Ann: Completion of Placement and Institutional Entitlement Offer, page-3

I think this post (https://hotcopper.com.au/posts/73093226/single)
by @mason also applies to Clarity for the following reasons:

- Clarity is in the oncology space which is highly critical, very expensive treatment, and a current hotbed for M&A activity

- Clarity is likely First-in-class (FIC) and Best-in-class (BIC) in TCT’s as both a Dx & Tx especially with >24 hr imaging and 2mm lesion detection (high specificity)

- The trials to date have proven to be highly effective, safe and also requested by EAP for prolonged use

- Bombesin is proving to be a boon to those not expressing PSA and hence a potential niche/ orphan market?

- Sartate etc are cherry on the cake

- My guess is we may enter into breast cancer space shortly with the funding in place.

To top it all, we have a highly capable management who are technically and financially skilled and are just tying the bow on Clarity as the M&A deals are getting closer and there is bound to be news that would be attracting many suitors and this is amply acknowledged by Alan’s comment highlighted above.

AIMO. No advice.